2026-07-22T20:06:03Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/184912024-11-28T15:20:07Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Robles-Díaz, Mercedes author Nezic, Lana author Vujic-Aleksic, Vesna author Björnsson, Einar S. authoraffiliation [Robles-Díaz,M] Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Universidad de Málaga, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Málaga, Spain. [Nezic,L; Vujic-Aleksic,V] Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina. [Vujic-Aleksic,V] The Republic of Srpska Agency for Certification, Accreditation and Quality Improvement in Health Care, Banja Luka, Bosnia and Herzegovina. [Björnsson,ES] Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland [Björnsson,ES] Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 2024-02-19T15:31:50Z 2024-02-19T15:31:50Z 2021-10-27 10.3389/fphar.2021.744488 1663-9812 Frontiers in Pharmacology http://hdl.handle.net/10668/4485 34776963 http://hdl.handle.net/20.500.12105/18491 Introduction: Treatment is generally not available for drug-induced liver injury (DILI) patients except in some specific circumstances. The management of DILI is based on the withdrawal of the responsible drug and monitoring the patients and only a few patients need to be referred to a transplant center. Some studies on the role of ursodeoxycholic acid (UDCA) in DILI have been published. The aim of this study was to perform a systematic review of the role of UDCA in the treatment and prevention of DILI. Methods: A search was undertaken in PubMed, with the key words ursodeoxycholic acid, drug-induced liver injury and hepatotoxicity following the PRISMA guidelines. Results: A total of 33 publications were identified: 25 case reports and 8 case series. In 18 of the 25 cases reports (22 patients), authors reported improvement of liver injury associated with UDCA therapy whereas 7 case reports did not show clinical or biochemical improvement after UDCA treatment. There were 4 studies evaluating the role of UDCA in the treatment of DILI, three prospective (one being a clinical trial) and one retrospective studies. Three studies observed liver profile improvements associated with UDCA. In addition, four studies evaluated UDCA in the prevention of DILI: one pilot study, two randomized clinical trials (RCT) and one retrospective study. Three of these studies observed a lower percentage of patients with an increase in transaminases in the groups that used UDCA for DILI prevention. Conclusion: According to available data UDCA seems to have some benefits in the treatment and prevention of DILI. However, the design of the published studies does not allow a firm conclusion to be drawn on the efficacy of UDCA in DILI. A well designed RCT to evaluate the role of UDCA in DILI is needed. eng Ursodeoxycholic acid Drug-induced liver injury Hepatotoxicity Treatment Prevention Pilot study PubMed Ácido ursodesoxicólico Enfermedad hepática inducida por sustancias y drogas Terapéutica Prevención de enfermedades Proyectos piloto Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review review article